LXEO Lexeo Therapeutics Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: LXEO

Price (delayed)

$3.52

Market cap

$288.8M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.02

Enterprise value

$199.53M

?
Relative Growth: Rel. Growth: 16
Relative Strength: Rel. Strength: 7
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 11
Highlights
LXEO's equity has soared by 70% year-on-year
The EPS has surged by 69% year-on-year and by 23% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.lexeotx.com
Peers: NTLA CRSP EDIT QURE

Key stats

What are the main financial stats of LXEO

LXEO stock price

How has the Lexeo Therapeutics stock price performed over time
Intraday
-13.51%
1 week
-15.38%
1 month
-27.87%
1 year
-34.21%
YTD
-64.55%
QTD
-24.38%

Financial performance

How have Lexeo Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$95.12M
Net income
-$87.27M
Gross margin
N/A
Net margin
N/A
LXEO's net income is up by 24% YoY
The operating income has increased by 23% YoY and by 2.7% from the previous quarter

Price vs fundamentals

How does LXEO's price correlate with its fundamentals

Growth

What is Lexeo Therapeutics's growth rate over time

Valuation

What is Lexeo Therapeutics stock price valuation
LXEO P/E details
P/E
N/A
P/B
1.18
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 69% year-on-year and by 23% since the previous quarter
LXEO's equity has soared by 70% year-on-year
The P/B is 41% below the last 4 quarters average of 2.3

Efficiency

How efficient is Lexeo Therapeutics business performance
Lexeo Therapeutics's ROIC has soared by 65% YoY and by 6% from the previous quarter
Lexeo Therapeutics's return on equity has surged by 56% YoY and by 12% QoQ
The ROA has grown by 48% YoY and by 9% from the previous quarter

Dividends

What is LXEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LXEO.

Financial health

How did Lexeo Therapeutics financials performed over time
Lexeo Therapeutics's total liabilities has decreased by 48% YoY but it has increased by 5% from the previous quarter
The company's total assets rose by 45% YoY
The debt is 97% less than the equity
LXEO's equity has soared by 70% year-on-year
The debt to equity has plunged by 50% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.